DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for dysthymic disorder — screening already-approved drugs against its 40-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDysthymic disorder maps to a 40-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dysthymic disorder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
VRK serine/threonine kinase 2 (VRK2) — VRK2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet sindrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2V62 · 1.7 Å · ligand SUCCINIC ACID (SIN). Experimental structure, not a prediction.
What the evidence adds up to
A 2011 meta-analysis of 17 double-blind, randomised, placebo-controlled trials found that antidepressant therapy was significantly more effective than placebo in dysthymic disorder, with a risk ratio of 1.75 (95% CI, 1.49–2.04; P < .0001). The placebo response rate in dysthymic disorder trials was 29.9%, significantly lower than the 37.9% seen in major depressive disorder (MDD) trials (P = .042). Meta-regression indicated a statistically significant difference in the risk ratio of responding to antidepressants versus placebo when comparing dysthymic disorder studies with MDD studies, favouring a greater risk ratio for antidepressant response in dysthymic disorder (coefficient of −0.113; P = .007). The authors concluded that the margin of efficacy of antidepressants for dysthymic disorder was larger than for MDD.
A 1999 study of 22 patients with dysthymia reported that their euthymic periods lasted from 2 to 30 days, with a mean of 8.0 days (SD = 6.6). The author noted that the DSM-IV criterion of a euthymic period of up to 2 months might confound the results of clinical trials. A 1998 review supported the use of pharmacotherapy for dysthymic disorder, with special emphasis on fluoxetine, and also discussed psychotherapy. A 2009 review stated that dysthymic disorder is a mild but chronic depression with a high risk of relapse, and that guidelines suggest treatment with antidepressants, especially selective serotonin reuptake inhibitors, and psychotherapy. A 2003 review similarly discussed treatment studies for psychotherapy, pharmacotherapy, and combined treatment, and offered an expert opinion on problems in the definition of dysthymic disorder.
The 2011 meta-analysis is the strongest evidence available, but it is based on only 17 trials, and the authors noted that future studies providing longer-term data on treatment with antidepressants are essential. The 1999 study had a very small sample (N = 22) and the 1998, 2009, and 2003 reviews are narrative summaries, not systematic analyses. What remains missing are large, long-term, randomised trials that account for the brief euthymic periods typical of dysthymia, and that test whether any specific antidepressant or combination with psychotherapy improves sustained remission rather than just short-term response. No trial has yet demonstrated a cure or a reliably durable treatment effect.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Clinical Psychiatry · 2011 · 82 citations
Efficacy of Antidepressants for Dysthymia
AbstractOBJECTIVE: The authors sought to determine the efficacy of antidepressants in dysthymic disorder and to compare antidepressant and placebo response rates between major depressive disorder (MDD) and dysthymic disorder. DATA SOURCES: PubMed/MEDLINE databases were searched for double-blind, randomized, placebo-controlled trials of antidepressants used as monotherapy for treatment of MDD or dysthymic disorder. We defined antidepressants as those with a letter of approval by the US, Canadian, or European Union drug regulatory agencies for treatment of MDD or dysthymic disorder, which included the following: amitriptyline, nortriptyline, imipramine, desipramine, clomipramine, trimipramine, protriptyline, dothiepin, doxepin, lofepramine, amoxapine, maprotiline, amineptine, nomifensine, bupropion, phenelzine, tranylcypromine, isocarboxazid, moclobemide, brofaromine, fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, zimelidine, tianeptine, ritanserin, trazodone, nefazodone, agomelatine, venlafaxine, desvenlafaxine, duloxetine, milnacipran, reboxetine, mirtazapine, and mianserin. Eligible studies were identified by cross-referencing the search term placebo with each of the above-mentioned agents. The search was limited to articles published between January 1, 1980, and November 20, 2009 (inclusive). To expand our database, we also reviewed the reference lists of the identified studies. STUDY SELECTION: We selected randomized, double-blind, placebo-controlled trials of antidepressants for either MDD or dysthymic disorder according to preset criteria relating to comorbidities, patient age, drug formulation, study duration, diagnostic criteria, choice of assessment scales, and whether or not the study reported original data. Final selection of articles was determined by consensus among the authors. RESULTS: A total of 194 studies were found that were eligible for inclusion in our analysis. Of these, 177 focused on the treatment of MDD and 17 on the treatment of dysthymic disorder. We found that antidepressant therapy was significantly more effective than placebo in dysthymic disorder (risk ratio = 1.75; 95% CI, 1.49-2.04; P < .0001), while placebo response rates in dysthymic disorder trials were significantly lower compared to MDD trials (29.9% vs 37.9%, respectively; P = .042). Meta-regression suggested a statistically significant difference in the risk ratio of responding to antidepressants versus placebo when comparing studies either on dysthymic disorder or on MDD, suggesting a greater risk ratio for response in favor of antidepressant therapy versus placebo in patients with dysthymic disorder versus MDD (coefficient of -0.113; P = .007). CONCLUSIONS: These results support the utility of antidepressants for dysthymic disorder. In fact, the margin of efficacy of antidepressants for dysthymic disorder was larger than for MDD. Future studies providing longer-term data on the treatment of dysthymic disorder with antidepressants are essential.
American Journal of Psychiatry · 1999 · 9 citations
Duration of Periods of Euthymia in Patients With Dysthymic Disorder
AbstractOBJECTIVE: The purpose of this study was to assess the duration of periods of euthymia in patients with dysthymia. METHOD: All patients with dysthymia who came to the Center for Anxiety and Depression over a 10-month period (N = 22) were interviewed by the author regarding the duration of their euthymic episodes. RESULTS: The 22 patients with dysthymia reported euthymic periods from 2 to 30 days (mean = 8.0 days, SD = 6.6). CONCLUSIONS: The euthymic period of up to 2 months that is specified in DSM-IV for dysthymic disorder might confound the results of clinical trials. Data from additional groups of dysthymic patients would be useful when considering this issue for DSM-V.
The Journal of Clinical Psychiatry · 2009 · 5 citations
Practical Strategies for Diagnosing and Treating Depression in Women at Midlife and Beyond:
AbstractDysthymic disorder is a mild but chronic depression that can be difficult for physicians to treat because patients with dysthymic disorder have a high risk of relapse. Guidelines for treating dysthymic disorder suggest treatment with antidepressants, especially selective serotonin reuptake inhibitors, and psychotherapy. A variety of antidepressants and psychotherapies have shown efficacy in trials, and treatment must be tailored to the individual patient.
Expert Review of Neurotherapeutics · 2003 · 1 citations
Current therapeutic approaches for dysthymic disorder
AbstractThe purpose of this article is to review the literature regarding current treatments for dysthymic disorder. We will first discuss definitions of dysthymic disorder, demographics of these patients, clinical course and family history. We will then review treatment studies for psychotherapy, pharmacotherapy and combined treatment, discuss treatment guidelines for dysthymic disorder, render an 'expert opinion' regarding problems in the definition of dysthymic disorder, elaborate on areas for future research and speculate on a 'five-year view.'
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
